RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Luye Pharma Group Stock

Luye Pharma Group Stocks 2024

Luye Pharma Group Stocks

3.73 B

Ticker

2186.HK

ISIN

BMG570071099

WKN

A116Z9

In 2024, Luye Pharma Group had 3.73 B outstanding stocks, a 0% change from the 3.73 B stocks in the previous year.

The Luye Pharma Group Stocks history

YEARNUMBER OF STOCKS (undefined CNY)
2026e3.73
2025e3.73
2024e3.73
20233.73
20223.48
20213.45
20203.19
20193.22
20183.22
20173.26
20163.32
20153.32
20142.99
20132.65
20122.65
20110.49
20100.49
20090.49
20080.49
20070.49
20060.46
20050.41
20040.3

Luye Pharma Group shares outstanding

The number of shares was Luye Pharma Group in 2023 — This indicates how many shares 3.728 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Luye Pharma Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Luye Pharma Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Luye Pharma Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Luye Pharma Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Luye Pharma Group Aktienanalyse

What does Luye Pharma Group do?

The Luye Pharma Group Ltd is a leading company in the pharmaceutical industry that offers a wide range of high-quality therapeutics and healthcare products to its customers. The company was founded in 1994 and is headquartered in Yantai, China. The history of the Luye Pharma Group Ltd dates back to 1994 when it was established as a small research and development unit. Since then, the company has grown into a global corporation operating in over 80 countries. In recent years, the Luye Pharma Group Ltd has expanded its drug manufacturing through the integration of CDMO Services and has also been involved in many mergers and acquisitions. The business model of the Luye Pharma Group Ltd is based on a wide product portfolio that encompasses research and development as well as manufacturing. The company has a strong product portfolio in the areas of neurology, oncology, cardiometabolic diseases, and sleep medicine. Its various business units work on the development, production, and marketing of innovative medications and healthcare products. The Luye Pharma Group Ltd is divided into several divisions specialized in meeting the requirements and needs of different customers: 1. Neurology: This division focuses on the research and development of medications for the treatment of neurological disorders and psychiatric conditions. The company offers a variety of products for epilepsy, Alzheimer's disease, Parkinson's disease, and depression. 2. Oncology: This division develops and manufactures drugs for the treatment of cancer. The company has a range of products for breast cancer, bladder cancer, prostate cancer, and lung cancer. 3. Cardiometabolic Diseases: This division offers a product range that includes medications for the treatment of diabetes and hypertension, as well as for the prevention and treatment of cardiovascular diseases. 4. Sleep Medicine: This division provides a wide portfolio of sleep and sedative medications without the well-known side effects such as sedation or respiratory problems. The company is also focusing on technologies such as nanoparticles, probiotics, and new delivery forms to further enhance the category of medications. Luye Pharma Group Ltd offers a wide range of high-quality medications and healthcare products. Some of its well-known products include Seroquel XR for the treatment of depression and bipolar disorders, Lipusuap for the treatment of breast cancer, Zuclopenthoxil hydrochloride for the treatment of schizophrenia, Cozaar for the treatment of hypertension, Risperidone for the treatment of psychotic disorders, and Yitian as a natural sleep aid. In summary, the Luye Pharma Group Ltd is a leading manufacturer of medications and healthcare products with a wide product range ranging from neurology to oncology and sleep and sedative therapeutics. The company is headquartered in Yantai, China, and is represented in over 80 countries. The Luye Group has strengthened its position in the global market through numerous acquisitions in recent years. Luye Pharma Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Luye Pharma Group's Shares Outstanding

Luye Pharma Group's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Luye Pharma Group’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Luye Pharma Group’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Luye Pharma Group’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Luye Pharma Group stock

How many stocks are there of Luye Pharma Group?

The current number of stocks of Luye Pharma Group is 3.73 B undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Luye Pharma Group are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Luye Pharma Group evolved in recent years?

The number of shares of Luye Pharma Group has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Luye Pharma Group as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Luye Pharma Group?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Luye Pharma Group pay?

Over the past 12 months, Luye Pharma Group paid a dividend of 0.06 CNY . This corresponds to a dividend yield of about 2.05 %. For the coming 12 months, Luye Pharma Group is expected to pay a dividend of 0 CNY.

What is the dividend yield of Luye Pharma Group?

The current dividend yield of Luye Pharma Group is 2.05 %.

When does Luye Pharma Group pay dividends?

Luye Pharma Group pays a quarterly dividend. This is distributed in the months of October, July, October, July.

How secure is the dividend of Luye Pharma Group?

Luye Pharma Group paid dividends every year for the past 3 years.

What is the dividend of Luye Pharma Group?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Luye Pharma Group located?

Luye Pharma Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Luye Pharma Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Luye Pharma Group from 7/24/2020 amounting to 0.06 CNY, you needed to have the stock in your portfolio before the ex-date on 6/29/2020.

When did Luye Pharma Group pay the last dividend?

The last dividend was paid out on 7/24/2020.

What was the dividend of Luye Pharma Group in the year 2023?

In the year 2023, Luye Pharma Group distributed 0 CNY as dividends.

In which currency does Luye Pharma Group pay out the dividend?

The dividends of Luye Pharma Group are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Luye Pharma Group

Our stock analysis for Luye Pharma Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Luye Pharma Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.